<?xml version="1.0" encoding="UTF-8"?>
 
<studies>
    <study>
        <shortTitle>Ph 4, DB, MC, Rand, Cross-over study to compare Multihance vs Omniscan in MRI of
            the brain</shortTitle>
        <longTitle>Phase IV, Double-Blind, Multi-Center, Randomized, Cross-Over Study to Compare
            0.10 mmol/kg of Multihance with 0.10 mmol/kg of Omniscan in Magnetic Resonance Imaging
            (MRI) of the Brain</longTitle>
        <phaseCode>4</phaseCode>
        <primarySponsorCode>Bracco</primarySponsorCode>
        <ctcVersion><name>2</name></ctcVersion>
        <identifiers>

            <identifier>
                <type>Local Identifier</type>
                <value>99B061</value>
                <source>WFUe</source>
                <primaryIndicator>No</primaryIndicator>
            </identifier>

            <identifier>
                <type>Protocol Authority Identifier</type>
                <value>99B063</value>
                <source>Bracco</source>
                <primaryIndicator>Yes</primaryIndicator>
            </identifier>
        </identifiers>
        <studySites>
            <studySite>
                <site>
                    <name>default</name>
                </site>
            </studySite>
        </studySites>
    </study>
    <!-- 
    <study>
        <shortTitle>Ph 2 study of the anti-CD20 antibody, SGn-30, in comb w/gem, vinorelbine and peg
            lipo dox (GVD) for re</shortTitle>
        <longTitle>Phase II Study of the Anti-CD30 Antibody, SGN-30 in Combination with Gemcitabine,
            Vinorelbine, and Pegylated Liposomal Doxorubicin (GVD) for Patients with Relapsed
            Refractory Hodgkin Lymphoma</longTitle>
        <description>Hodgkins Lymphoma,CALGB</description>
        <multiInstitutionIndicator>true</multiInstitutionIndicator>
        <phaseCode>2</phaseCode>
        <primarySponsorCode>CALGB</primarySponsorCode>
        <identifiers>
            <identifier>
                <type>Local Identifier</type>
                <value>50502</value>
                <source>WFU</source>
                <primaryIndicator>No</primaryIndicator>
            </identifier>
            <identifier>
                <type>Protocol Authority Identifier</type>
                <value>50502</value>
                <source>CALGB</source>
                <primaryIndicator>Yes</primaryIndicator>
            </identifier>
        </identifiers>
        <studySites>
            <studySite>
                <site>
                    <name>default</name>
                </site>
            </studySite>
        </studySites>
    </study>
    <study>

        <shortTitle>Ph 4, DB, MC, Rand, Cross-over study to compare Multihance vs Omniscan in MRI of
            the brain</shortTitle>
        <longTitle>Phase IV, Double-Blind, Multi-Center, Randomized, Cross-Over Study to Compare
            0.10 mmol/kg of Multihance with 0.10 mmol/kg of Omniscan in Magnetic Resonance Imaging
            (MRI) of the Brain</longTitle>
        <description>Brain and Nervous System,INDUSTRY</description>
        <multiInstitutionIndicator>true</multiInstitutionIndicator>
        <phaseCode>4</phaseCode>
        <primarySponsorCode>Bracco</primarySponsorCode>
        <identifiers>

            <identifier>
                <type>Local Identifier</type>
                <value>99B06</value>
                <source>WFU</source>
                <primaryIndicator>No</primaryIndicator>
            </identifier>

            <identifier>
                <type>Protocol Authority Identifier</type>
                <value>99B06</value>
                <source>Bracco</source>
                <primaryIndicator>Yes</primaryIndicator>
            </identifier>
        </identifiers>
        <studySites>
            <studySite>
                <site>
                    <name>default</name>
                </site>
            </studySite>
        </studySites>
    </study>
    <study>
        <shortTitle>Ph 1/2 study of hypo-frac stereotactic body RT for st 1/2 NSCLC within the
            central lung reg and the</shortTitle>
        <longTitle>A Phase I/II Study of Hypofractionated Stereotactic Body Radiotherapy for Stage
            I/II Non-Small Cell Lung Cancer with the Central Lung Region and the Prognostic Impact
            of FDG Positron Emission Tomography</longTitle>
        <description>Lung,CCCWFU</description>
        <multiInstitutionIndicator>true</multiInstitutionIndicator>
        <phaseCode>1/2</phaseCode>
        <primarySponsorCode>CCCWFU</primarySponsorCode>
        <identifiers>

            <identifier>
                <type>Protocol Authority Identifier</type>
                <value>62206</value>
                <source>WFU</source>
                <primaryIndicator>Yes</primaryIndicator>
            </identifier>
        </identifiers>
        <studySites>
            <studySite>
                <site>
                    <name>default</name>
                </site>
            </studySite>
        </studySites>
    </study>
    -->
</studies>